No difference in clinical outcomes was found between subjects with HIV randomly assigned to a non-nucleoside reverse-transcriptase inhibitor (NNRTI) versus ritonavir-boosted protease inhibitor (PI/r)-based initial antiretroviral therapy (ART).
IDWeek 2014: HIV
Want to read more?
Please login or register first to view this content.